Gamida Cell ltd
11
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
18.2%
2 terminated/withdrawn out of 11 trials
77.8%
-8.7% vs industry average
27%
3 trials in Phase 3/4
86%
6 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Motixafortide for MRD Sensitization in AML
Role: collaborator
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Role: lead
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Role: collaborator
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Role: lead
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Role: lead
Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
Role: lead
Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies
Role: lead
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Role: lead
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Role: lead
Umbilical Cord Transplantation for the Elderly Population
Role: collaborator
Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
Role: lead
All 11 trials loaded